Piper Sandler Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target cut by equities researchers at Piper Sandler from $40.00 to $15.00 in a report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s target price suggests a potential upside of 38.12% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Truist Financial dropped their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research note on Friday. Finally, TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Price Performance

Shares of KROS opened at $10.86 on Friday. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00. The company has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. The stock has a 50-day moving average of $36.37 and a 200-day moving average of $47.13.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same period in the previous year, the business earned ($1.33) earnings per share. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. Analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in Keros Therapeutics by 20.6% in the second quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock worth $1,903,000 after acquiring an additional 7,111 shares during the period. American Century Companies Inc. increased its stake in shares of Keros Therapeutics by 24.9% during the 2nd quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock worth $13,626,000 after purchasing an additional 59,364 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $654,000. XTX Topco Ltd purchased a new position in Keros Therapeutics in the second quarter valued at approximately $228,000. Finally, Integral Health Asset Management LLC lifted its stake in Keros Therapeutics by 112.5% in the second quarter. Integral Health Asset Management LLC now owns 85,000 shares of the company’s stock valued at $3,884,000 after purchasing an additional 45,000 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.